Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01462448
Other study ID # 20429
Secondary ID HU0001-11-1-0005
Status Active, not recruiting
Phase
First received
Last updated
Start date March 2012
Est. completion date August 2019

Study information

Verified date April 2019
Source Henry M. Jackson Foundation for the Advancement of Military Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine if there is a genetic component to phantom limb pain. DNA will be analyzed for single nucleotide polymorphisms (SNPs) between the control and phantom limb pain group. Total RNA will also be isolated and profiled to asses the degree to which our gene(s) of interest are expressed in the presence or absence of phantom limb pain. Some proteins, such as inflammatory antibodies or the neurotrophin brain-derived neurotrophic factor (BDNF), will also be assessed for their association(s) with phantom limb pain.


Description:

Most patients (90-95%)with major limb amputations experience a phantom limb--the vivid impression that the limb is still present. In many cases, the sensation is painful for reasons that are currently not well understood. A small subset of amputees (<10%) never experience phantom limb pain (PLP), the painful sensation felt in the amputated limb. This difference suggests that there may be a genetic component that precludes some patients from ever experiencing PLP. Understanding the genetic components of PLP may help in predicting which patients will experience PLP and which amputees will respond to the various treatment options available.

In order to understand the genetic aspects and ultimately develop more effective treatment options in the future, patients with and without PLP will be asked to give 30 mls of blood after overnight fasting. These blood samples will be de-identified and sent to the National Institutes of Health (NIH) in Bethesda, Maryland, where all of the genetic analyses will take place.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 726
Est. completion date August 2019
Est. primary completion date April 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Chronic PLP Group:

- At least 18 years of age.

- Written informed consent and written authorization for use or release of health and research study information

- Single or multiple upper and/or lower limb amputation

- At least three months post-amputation

- Ability to follow study instructions and likely to complete required visit(s)

- Experienced PLP for at least one month and at least 3 times per week

- Phantom limb pain differentiated from residual limb pain by physical exam.

- Subjects taking blood thinners or other medications that do not increase risk during a blood draw.

Non-Chronic PLP Group:

- At least 18 years of age.

- Written informed consent and written authorization for use or release of health and research study information

- Single or multiple upper and/or lower limb(s) amputation

- At least three months post-amputation

- Ability to follow study instructions and likely to complete required visit(s)

- Experienced PLP less than 10 times total and/or for less than two weeks

- Subjects taking blood thinners or other medications that do not increase risk during a blood draw.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Blood Draw
Single blood draw of 30 ml

Locations

Country Name City State
United States Walter Reed National Military Medical Center (WRNMMC) Bethesda Maryland

Sponsors (2)

Lead Sponsor Collaborator
Henry M. Jackson Foundation for the Advancement of Military Medicine Uniformed Services University of the Health Sciences

Country where clinical trial is conducted

United States, 

References & Publications (6)

Jensen TS, Krebs B, Nielsen J, Rasmussen P. Phantom limb, phantom pain and stump pain in amputees during the first 6 months following limb amputation. Pain. 1983 Nov;17(3):243-56. — View Citation

Katz J, Melzack R. Pain 'memories' in phantom limbs: review and clinical observations. Pain. 1990 Dec;43(3):319-36. Review. — View Citation

Kooijman CM, Dijkstra PU, Geertzen JH, Elzinga A, van der Schans CP. Phantom pain and phantom sensations in upper limb amputees: an epidemiological study. Pain. 2000 Jul;87(1):33-41. — View Citation

Montoya P, Larbig W, Grulke N, Flor H, Taub E, Birbaumer N. The relationship of phantom limb pain to other phantom limb phenomena in upper extremity amputees. Pain. 1997 Aug;72(1-2):87-93. — View Citation

Ramachandran VS, Hirstein W. The perception of phantom limbs. The D. O. Hebb lecture. Brain. 1998 Sep;121 ( Pt 9):1603-30. Review. — View Citation

Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. Pain. 1984 Jan;18(1):83-95. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of Unique Single Nucleotides Polymorphisms (SNPs) associated with Phantom Limb Pain (PLP) The primary outcome measure for this study is the identification of unique SNPs that may correlate with PLP. Patients will undergo a one-time blood draw and fill out a survey characterizing their phantom limb pain. The PLP characteristics along with DNA analysis using Affymetrix SNP chip technology will be used to match genotype with phenotype. 5 years
Secondary Correlation between Phantom Limb Pain (PLP) and Blood Levels of Antibodies Associated with Peripheral Nerve Damage The underlying hypothesis of the secondary outcome measure is that damage to peripheral nerves provokes a humoral immune response to neuronal and glial proteins that can be detected by measuring specific antibodies in blood. The data obtained will lead to a more complete understanding of pathogenic mechanisms in PLP and potential biomarkers for sub-classification, prognosis, and intervention. 5 years
Secondary Correlation between Phantom Limb Pain (PLP) and Serum Levels of Brain-derived Neurotrophic Factor (BDNF) BDNF has been implicated in pain nociception and is therefore pertinent to our study of phantom limb pain. After peripheral nerve injury, BDNF expression is dramatically increased in pain receptors of the brainstem. 5 years
Secondary Correlation between Phantom Limb Pain (PLP) and Unique Transcribed RNA Many underlying causes for neuropathic pain involve changes in messenger ribonucleic acid (mRNA) levels because of altered gene expression or transcript stability. The study will isolate total RNA from blood and measure the relative amounts of transcribed RNA under the condition of phantom limb pain or no phantom limb pain. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT00388752 - Acupuncture for the Treatment of Phantom Limb and Residual Limb Pain After Amputation Phase 1
Completed NCT01462461 - Virtual Integrated Environment in Decreasing Phantom Limb Pain N/A
Completed NCT00667264 - Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain N/A
Terminated NCT00768248 - Naval Medical Center San Diego (NMCSD) - Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain N/A
Recruiting NCT02684201 - Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees N/A
Completed NCT00731614 - Cognitive Behavior Therapy (CBT) and Mirror Training for Phantom Limb Pain N/A
Recruiting NCT00301444 - A Study to Test the Effectiveness of Mirror-Box and Mental Visualization Treatments on Phantom Limb Pain N/A
Completed NCT05247827 - The Effects of Targeted Phantom Motor Execution on Phantom Limb Control N/A
Terminated NCT00427947 - Leg Amputation and Continuous Sciatic Nerve Block Phase 3
Recruiting NCT03592901 - Phantom Limb Experience After Brachial Plexus Anesthesia